Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Introduction
00:00 • 2min
Wigovi: A Weight Loss Drug That Reduced the Risk of Major Cardiovascular Complications
01:37 • 2min
Wigovi and Cardiovascular Health
03:42 • 3min
The Relationship Between Weight Loss and Heart Health
06:17 • 2min
Novo's Approach to Weight Loss
07:58 • 2min
Novo's Acquisition of Inversago Targets the Cannabinoid Receptor CB1
10:15 • 2min
The Importance of a Presentation at the American Heart Association
12:06 • 2min
The Wall Street Side of Obesity
14:08 • 2min
The Myth of Lilly's $1 Trillion Market Cap
16:11 • 3min
The Dynamics of Pharmaceuticals
18:45 • 2min
The Future of Healthcare Brand Loyalty
20:28 • 2min
The Competition Between Novo and Lilly in the Diabetes Market
22:31 • 2min
Denanamab: The Next Biggest Opportunity for the Stock
24:14 • 2min
The Future of Lilly's Drugs
25:55 • 3min
The Rise of Obesity in Healthcare
29:09 • 3min